Original filing text · Part I

Item 3 — Quantitative and Qualitative Disclosures About Market Risk

Viridian Therapeutics, Inc.\de · 10-Q · Q2 FY2026 · Period ended Jun 30, 2026

This is the extracted source text from the SEC filing. Formatting may differ from the original document.

There were no material changes to our market risks in the six months ended June 30, 2026, when compared to the disclosures in Item 7A of our 2025 Annual Report on Form 10-K.